[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Anita Saraf\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100536071",false,"NCT06260059","Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease","Efficacy of Sodium Glucose Transporter Inhibitor (SGLT2i) in Adult Patients With Congenital Heart Disease","EmpaCHD","Inclusion Criteria:\n\n* Diagnoses of Congenital Heart Disease\n* Age 18+\n* ACHD level of structural complexity II or III\n* Recent (\\\u003C6 months) decrease in systemic Ejection Fraction (confirmed by cardiac Echocardiogram, Computed Tomography or cMRI) to EF \\\u003C 60%\n* Recent decrease in systemic ejection fraction confirmed by cardiac Echo, CT or MRI by \\> 5% in the last 6 months or less.\n* Must be able to complete neurocognitive assessments on a handheld computer.\n\nExclusion Criteria:\n\n* Diagnosed with Diabetes\n* Contraindication to Jardiance\u002FEntresto or any heart failure medication (per guideline-directed therapy, 2022).\n* Previous therapy with Jardiance at \\\u003C4 weeks\n* Glomerular Filtration Rate \\\u003C20\n* Pregnancy, breastfeeding, or planning to become pregnant in the coming year\n* History of liver disease - including non-alcoholic fatty liver disease (NAFLD) and cirrhosis\n* History of inborn error(s) of metabolism (including but is not exclusive of Glycogen storage disease type 1)\n* Glucose-galactose malabsorption, familial hyperinsulinism, maple syrup urine disease,\n* Gaucher disease,\n* Tay-Sachs disease,\n* Mucolipidosis IV,\n* Niemann-Pick disease,\n* Type A mitochondrial disease,\n* Metabolic disorders related to glucose metabolism","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD).",[26,27],"Adult Congenital Heart Disease","Heart Failure",[29,30,31],"congenital heart disease","reduced exercise capacity","decreased cardiac function","RECRUITING","2025-10-02",{"date":35,"type":36},"2025-10-06","ACTUAL",{"date":38,"type":36},"2024-09-17",{"date":40,"type":20},"2027-06-01",{"name":42,"class":43},"Anita Saraf","OTHER",3,""]